Loomis Sayles & Co. L P Trims Stake in IQVIA Holdings Inc. (NYSE:IQV)

Loomis Sayles & Co. L P cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 696,700 shares of the medical research company’s stock after selling 71,337 shares during the quarter. Loomis Sayles & Co. L P owned about 0.38% of IQVIA worth $165,097,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA during the 3rd quarter worth approximately $147,683,000. 1832 Asset Management L.P. grew its stake in shares of IQVIA by 472.3% in the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after buying an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new position in IQVIA during the 2nd quarter worth about $70,610,000. Impax Asset Management Group plc boosted its holdings in IQVIA by 19.3% during the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after acquiring an additional 264,555 shares during the period. Finally, Canada Pension Plan Investment Board increased its stake in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 6.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Up 2.1 %

IQV opened at $201.82 on Monday. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market capitalization of $36.63 billion, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51. The business’s 50-day simple moving average is $222.67 and its 200-day simple moving average is $227.16.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Evercore ISI lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Robert W. Baird decreased their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.